GeneDx (Nasdaq: WGS), a leader in genomic diagnostics, has announced two strategic leadership appointments designed to accelerate its transformation into a precision medicine powerhouse. The company appointed Lisa Gurry as Chief Business Officer and Dr. Thomas Fuchs, Chief AI Officer at Eli Lilly and Company, to its board of directors.
Strategic Business Leadership Addition
In her newly-created role as Chief Business Officer, Gurry will spearhead GeneDx's next phase of transformation, focusing on advancing data and information services across biopharma, health systems, and other strategic partners. Her primary mandate involves architecting and operating strategic business operations and partnership models to unlock the full potential of GeneDx Infinity™, the company's flagship dataset containing nearly one million exomes and genomes paired with more than seven million phenotypic datapoints.
"As the largest provider of rare disease diagnosis in the world, GeneDx is uniquely positioned to enable drug discovery and development, fueling the future of precision medicine with the most enriched genomic insights," said Katherine Stueland, President and CEO of GeneDx. "With the power of GeneDx Infinity, Lisa will help us drive value and better patient outcomes by delivering genomic insights across health systems and biopharma."
Gurry brings extensive experience at the intersection of healthcare, technology, and data. She co-founded Truveta, where she built the growth engine that delivered strategic partnerships with more than 100 organizations across life sciences, healthcare, public health, and academic research. Prior to Truveta, she spent over two decades at Microsoft driving global growth strategies for Windows, Office, and Xbox.
AI Expertise Joins Board
The appointment of Dr. Fuchs to the board of directors represents a significant strategic move to advance GeneDx's AI capabilities. As SVP and Chief AI Officer at Lilly, Dr. Fuchs provides vision, strategic direction, and overall leadership of AI initiatives for drug discovery, clinical trials, manufacturing, commercial activities, and internal functions.
"With the world's largest rare disease data set, we're only beginning to realize AI's full potential to deliver faster, more precise insights to clinicians and families, accelerating answers for those who need them most," said Stueland. "Dr. Fuchs' experience scaling AI and machine learning infrastructure and algorithms for practical, high-impact applications in diagnostic medicine is invaluable."
Dr. Fuchs previously served as Dean and inaugural Department Chair for AI and Human Health at Mount Sinai, Director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the endowed Barbara T. Murphy Professor for AI and Computational Pathology at the Icahn School of Medicine at Mount Sinai. He also founded three companies, including Paige AI, and holds a doctoral degree in machine learning from ETH Zurich.
AI-Powered Diagnostic Innovation
These leadership appointments build on GeneDx's recent AI initiatives. Earlier this year, the company unveiled Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining workflows, and enhancing clinical insights. GeneDx also acquired Fabric Genomics, a pioneer in AI-driven genomic interpretation.
"Fighting rare diseases, particularly in support of the pediatric population, is a deeply meaningful mission," said Dr. Fuchs. "GeneDx's commitment to genomic medicine and leveraging AI can significantly increase the ability to deliver meaningful insights and improve patient outcomes."
Market Position and Dataset Advantage
GeneDx Infinity represents an unmatched resource in rare disease research, built over 25 years from millions of genomic tests and deep clinical insights. This dataset powers the company's ExomeDx and GenomeDx tests, providing clinicians with enhanced diagnostic capabilities. The platform serves as a critical resource for biopharma partners seeking to accelerate drug development and bring targeted therapies to market faster.
The company positions itself at the nexus of rare disease diagnosis, moving healthcare from reactive sick care to proactive healthcare. While rooted in rare disease diagnosis, GeneDx's commitment extends to serving as a trusted partner throughout patients' lives, supporting families at every stage of their healthcare journey.
